High-dose esomeprazole in combination with aspirin can moderately reduce the risk of developing high-grade dysplasia or oesophageal cancer or delay death from any cause in patients with Barrett’s oesophagus (BE).
The selective PI3K inhibitor taselisib in combination with fulvestrant has demonstrated efficacy in patients with oestrogen receptor (ER)-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.
The EGFR tyrosine kinase inhibitor (TKI) dacomitinib showed superior overall survival (OS) vs gefitinib in patients with treatment-naïve EGFR-positive non-small-cell lung cancer (NSCLC) in the final analysis of the ARCHER 1050 study.
Adjuvant treatment with a modified FOLFIRINOX (mFOLFIRINOX) regimen extends overall survival (OS) by nearly 20 months compared with standard chemotherapy in patients with nonmetastatic pancreatic ductal adenocarcinoma (PDAC), results of a phase III trial have shown.
Most patients with advanced non-small-cell lung cancer (NSCLC) can have improved overall survival (OS) with first-line pembrolizumab without chemotherapy even if their PD-L1 expression levels are low, results of the phase III KEYNOTE-042 trial have shown.
Treatment with fludarabine, cytarabine and G-CSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (Ida) is associated with high remission rates among patients with newly diagnosed core binding factor acute myelogenous leukaemia (CBF-AML) with low induction mortalities, reports a study.
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves response rates and depth of response in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT), according to updated results of the phase II GRIFFIN* study presented at ASH 2019.
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.